Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 14;36(3):260-269.
doi: 10.4103/sjopt.sjopt_12_22. eCollection 2022 Jul-Sep.

Anti-vascular endothelial growth factor therapy in retinopathy of prematurity: An updated literature review

Asma K Alzuabi  1 , Ola M Alshammari  2 , Abdullah N Almousa  3 , Marwan A Abouammoh  3
Affiliations

Anti-vascular endothelial growth factor therapy in retinopathy of prematurity: An updated literature review

Asma K Alzuabi et al. Saudi J Ophthalmol. .

Abstract

Laser photocoagulation can still be considered the gold standard for treatment for retinopathy of prematurity (ROP). However, anti-vascular endothelial growth factor (anti-VEGF) therapy has increasingly become an important option that plays a significant role in the treatment of ROP. Major clinical trials have been published regarding the anti-VEGF use in ROP, along with multiple other studies looking into the different agents, doses, techniques, and possible complications. Anti-VEGF therapies can be considered as a safe and effective option for managing ROP. More longitudinal randomized clinical trials are necessary to evaluate the preferred treatment agent, the appropriate dose, best follow-up protocol, and the long-term ocular and systemic outcomes following treatment.

Keywords: Anti-vascular endothelial growth factor; follow-up; retinopathy of prematurity.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Wood EH, Chang EY, Beck K, Hadfield BR, Quinn AR, Harper CA. 80 Years of vision: Preventing blindness from retinopathy of prematurity. J Perinatol. 2021;41:1216–24. - PMC - PubMed
    1. Smith LE. Through the eyes of a child: Understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008;49:5177–82. - PubMed
    1. Chiang MF, Quinn GE, Fielder AR, Ostmo SR, Paul Chan RV, Berrocal A, et al. International classification of retinopathy of prematurity, third edition. Ophthalmology. 2021;128:e51–68. - PMC - PubMed
    1. Tasman W. Multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol. 1988;106:463–4. - PubMed
    1. Palmer EA, Hardy RJ, Dobson V, Phelps DL, Quinn GE, Summers CG, et al. 15-year outcomes following threshold retinopathy of prematurity: Final results from the multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol (Chicago, Ill 1960) 2005;123:311–8. - PubMed